Data


NOTE: A total of 278 participants included in analysis after removing exclusion criteria.

Descriptives

Patient demographics

Characteristic Conventional (n=141) Non-conventional (n=137) Total (n=278) P-value
Age (y)at the time of result: Mean (SD) 65.40 (15.10) 68.81 (14.64) 67.08 (14.95) 0.06
Age (y)at the time of result: N(%) 0.36
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<65 years 60 (42.6) 50 (36.5) 110 (39.57)
≥65 years 81 (57.4) 87 (63.5) 168 (60.43)
Gender: N(%) 0.58
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Male 90 (63.8) 82 (59.9) 172 (61.87)
Female 51 (36.2) 55 (40.1) 106 (38.13)
Inpatient length of stay: Median (IQ range) 12.00 (6.00-24.00) 14.00 (8.00-25.00) 13.00 (7.00-24.75) 0.18
Height (cm): Mean (SD) 171.19 (10.34) 170.45 (10.39) 170.83 (10.35) 0.55
Weight (kg)within the week prior to dose: Mean (SD) 88.02 (26.93) 98.32 (41.03) 93.10 (34.92) 0.01
BMI: Median (IQ range) 28.93 (24.23-33.71) 29.45 (24.97-39.68) 29.10 (24.43-35.06) 0.13
BMI: N(%) 0.92
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<30 kg/m2 77 (54.6) 73 (53.3) 150 (53.96)
≥30 kg/m2 64 (45.4) 64 (46.7) 128 (46.04)
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: Mean (SD) 50.35 (27.86) 48.33 (23.15) 49.25 (25.36) 0.60
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: N(%) 0.002
Missing 58 (41.1) 39 (28.5) 97 (34.89)
Stage 1: >=90 ml/min 0 (0.0) 2 (1.5) 2 (0.72)
Stage 2: 60-89 ml/min 37 (26.2) 26 (19.0) 63 (22.66)
Stage 3: 30-59 ml/min 21 (14.9) 49 (35.8) 70 (25.18)
Stag3 4/5: <30 ml/min 25 (17.7) 21 (15.3) 46 (16.55)
modified CG (mL/min): Mean (SD) 65.27 (36.25) 55.33 (33.27) 60.37 (35.11) 0.02
CrCl (mL/min): N(%) 0.003
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<50 ml/min 52 (36.9) 76 (55.5) 128 (46.04)
≥50 ml/min 89 (63.1) 61 (44.5) 150 (53.96)
LMWH level: Mean (SD) 0.88 (0.35) 0.79 (0.32) 0.84 (0.34) 0.02
LMWH >1.0: N(%) 0.02
Missing 0 (0.0) 0 (0.0) 0 (0.00)
≤1.0 96 (68.1) 111 (81.0) 207 (74.46)
>1.0 45 (31.9) 26 (19.0) 71 (25.54)
LMWH 0.09
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<0.5 13 (9.2) 23 (16.8) 36 (12.95)
≥0.5 128 (90.8) 114 (83.2) 242 (87.05)
Enoxaparin dose used (mg): Mean (SD) 88.19 (25.46) 77.55 (32.75) 82.95 (29.71) 0.003
Enoxaparin dose (mg/kg): Mean (SD) 1.01 (0.12) 0.83 (0.30) 0.92 (0.24) <0.0001
Concurrent antiplatelet or anticoagulation treatment: N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
No 140 (99.3) 136 (99.3) 276 (99.28)
Yes 1 (0.7) 1 (0.7) 2 (0.72)
Clinical events after anticoagulation (choice=Death): N(%) 0.88
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 129 (91.5) 127 (92.7) 256 (92.09)
Checked 12 (8.5) 10 (7.3) 22 (7.91)
Clinical events after anticoagulation (choice=ACS): N(%) 0.49
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 141 (100.0) 136 (99.3) 277 (99.64)
Checked 0 (0.0) 1 (0.7) 1 (0.36)
Clinical events after anticoagulation (choice=VTE): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 139 (98.6) 135 (98.5) 274 (98.56)
Checked 2 (1.4) 2 (1.5) 4 (1.44)
Clinical events after anticoagulation (choice=Ischaemic stroke in hospital): N(%) 0.24
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 141 (100.0) 135 (98.5) 276 (99.28)
Checked 0 (0.0) 2 (1.5) 2 (0.72)
Major bleeding in hospital: N(%) 0.53
Missing 1 (0.7) 1 (0.7) 2 (0.72)
Yes 5 (3.5) 8 (5.8) 13 (4.68)
No 135 (95.7) 128 (93.4) 263 (94.60)
Indication for enoxaparin(choose as many as apply) (choice=Pulmonary embolism): N(%) 0.24
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 56 (39.7) 65 (47.4) 121 (43.53)
Checked 85 (60.3) 72 (52.6) 157 (56.47)
Indication for enoxaparin(choose as many as apply) (choice=Deep vein thrombosis): N(%) 0.07
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 71 (50.4) 85 (62.0) 156 (56.12)
Checked 70 (49.6) 52 (38.0) 122 (43.88)
Indication for enoxaparin(choose as many as apply) (choice=Atrial fibrillation): N(%) 0.38
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 117 (83.0) 107 (78.1) 224 (80.58)
Checked 24 (17.0) 30 (21.9) 54 (19.42)
Indication for enoxaparin(choose as many as apply) (choice=Myocardial infarction): N(%) 0.62
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 140 (99.3) 135 (98.5) 275 (98.92)
Checked 1 (0.7) 2 (1.5) 3 (1.08)
Indication for enoxaparin(choose as many as apply) (choice=Metallic heart valve): N(%) 0.73
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 136 (96.5) 130 (94.9) 266 (95.68)
Checked 5 (3.5) 7 (5.1) 12 (4.32)
Indication for enoxaparin (Other): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Yes 140 (99.3) 137 (100.0) 277 (99.64)
Other/Unknown 1 (0.7) 0 (0.0) 1 (0.36)

Subgroups

Anti-Xa >1.0 IU/mL

Characteristic Conventional (n=45) Non-conventional (n=26) Total (n=71) P-value
CrCl (mL/min): N(%) 0.94
<50 ml/min 19 (42.2) 12 (46.2) 31 (43.66)
≥50 ml/min 26 (57.8) 14 (53.8) 40 (56.34)
BMI: N(%) 0.12
<30 kg/m2 16 (35.6) 15 (57.7) 31 (43.66)
≥30 kg/m2 29 (64.4) 11 (42.3) 40 (56.34)
Age (y)at the time of result: N(%) 0.60
<65 years 18 (40.0) 8 (30.8) 26 (36.62)
≥65 years 27 (60.0) 18 (69.2) 45 (63.38)

Anti-Xa <0.5 IU/mL

Characteristic Conventional (n=13) Non-conventional (n=23) Total (n=36) P-value
CrCl (mL/min): N(%) 0.14
<50 ml/min 5 (38.5) 16 (69.6) 21 (58.33)
≥50 ml/min 8 (61.5) 7 (30.4) 15 (41.67)
BMI: N(%) 1.00
<30 kg/m2 8 (61.5) 15 (65.2) 23 (63.89)
≥30 kg/m2 5 (38.5) 8 (34.8) 13 (36.11)
Age (y)at the time of result: N(%) 0.69
<65 years 4 (30.8) 5 (21.7) 9 (25.00)
≥65 years 9 (69.2) 18 (78.3) 27 (75.00)

Anti-Xa (IU/mL): Median (IQR)

Conventional Non-conventional P-value
CrCl (mL/min): <50 ml/min 0.87 (0.66-1.14) 0.71 (0.51-0.90) 0.33
CrCl (mL/min): ≥50 ml/min 0.79 (0.62-1.02) 0.81 (0.60-0.99) 0.05
BMI: <30 kg/m2 0.76 (0.62-0.96) 0.76 (0.54-0.96) 0.005
BMI: ≥30 kg/m2 0.97 (0.73-1.16) 0.77 (0.56-0.94) 0.79
Age (y)at the time of result: <65 years 0.79 (0.64-1.02) 0.79 (0.59-0.94) 0.42
Age (y)at the time of result: ≥65 years 0.83 (0.66-1.09) 0.73 (0.52-0.95) 0.37

Model 1: All patients

Anti-Xa

Model specifications - Outcome: LMWH level
- Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency
- Model: Multiple linear regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

Global test

model term df1 df2 F.ratio p.value
individualised_dose_used 1 272 7.887 0.005
age 1 272 0.065 0.8
modified_cg 1 272 0.443 0.5
bmi 1 272 4.353 0.04
enoxaparin_freq 1 272 1.487 0.2

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -0.392 (-0.793, 0.010) 0.06
individualised_dose_usedNon-conventional -0.136 (-0.231, -0.041) 0.005
age 0.001 (-0.004, 0.005) 0.8
modified_cg -0.001 (-0.003, 0.001) 0.5
bmi 0.005 (0.000, 0.009) 0.04
enoxaparin_freqTwice daily 0.079 (-0.048, 0.207) 0.2

Model diagnostics

Results

Dosing strategy

Contrast Ratio of Geometric means (95% CI) P-value
(Non-conventional) / Conventional 0.873 (0.793, 0.960) 0.005

Adjusted means (95% CI)
individualised_dose_used response SE df lower.CL upper.CL
Conventional 0.812 0.031 272 0.753 0.876
Non-conventional 0.709 0.028 272 0.656 0.766

Modified CrCl

Contrast Ratio of Geometric means (95% CI) P-value
modified_cg61 / modified_cg60 0.999 (0.997, 1.001) 0.5

BMI

Contrast Ratio of Geometric means (95% CI) P-value
bmi30 / bmi29 1.005 (1.000, 1.009) 0.04

Age

Contrast Ratio of Geometric means (95% CI) P-value
age67 / age66 1.001 (0.996, 1.005) 0.8

Dose frequency

Contrast Ratio of Geometric means (95% CI) P-value
Twice daily / Once daily 1.082 (0.952, 1.230) 0.2

Anti-Xa>1.0

Model specifications - Outcome: LMWH level >1.0 (yes/no)
- Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
individualised_dose_used 9.484 1 0.002
age 0.476 1 0.5
modified_cg 3.641 1 0.06
bmi 3.815 1 0.05
enoxaparin_freq 2.739 1 0.10

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -0.754 (-3.104, 1.595) 0.5
individualised_dose_usedNon-conventional -0.918 (-1.517, -0.318) 0.003
age -0.009 (-0.034, 0.016) 0.5
modified_cg -0.011 (-0.023, 0.001) 0.06
bmi 0.025 (0.000, 0.050) 0.05
enoxaparin_freqTwice daily 0.687 (-0.151, 1.524) 0.1

Results

Dosing strategy

Contrast Odds ratios (95% CI) P-value
(Non-conventional) / Conventional 0.40 (0.22, 0.73) 0.003

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 0.99 (0.98, 1.00) 0.06

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 1.03 (1.00, 1.05) 0.05

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 0.99 (0.97, 1.02) 0.5

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 1.99 (0.86, 4.59) 0.1

Anti-Xa<0.5

Model specifications - Outcome: LMWH level <0.5 (yes/no)
- Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
individualised_dose_used 4.859 1 0.03
age 0.058 1 0.8
modified_cg 0.006 1 0.9
bmi 5.938 1 0.01
enoxaparin_freq 1.512 1 0.2

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -0.226 (-3.435, 2.982) 0.9
individualised_dose_usedNon-conventional 0.826 (0.076, 1.576) 0.03
age -0.004 (-0.036, 0.028) 0.8
modified_cg 0.001 (-0.014, 0.015) 0.9
bmi -0.049 (-0.093, -0.005) 0.03
enoxaparin_freqTwice daily -0.560 (-1.438, 0.319) 0.2

Results

Dosing strategy

Contrast Odds ratios (95% CI) P-value
(Non-conventional) / Conventional 2.28 (1.08, 4.84) 0.03

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 1.00 (0.99, 1.01) 0.9

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 0.95 (0.91, 0.99) 0.03

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 1.00 (0.96, 1.03) 0.8

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 0.57 (0.24, 1.38) 0.2

Model 2: Conventionally dosed patients

Anti-Xa

Model specifications - Outcome: LMWH level
- Covariates: age, modified CrCl, BMI, dosing frequency
- Model: Multiple linear regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

dat_run2 <- dat_run[dat_run$individualised_dose_used%in%"Conventional",]

Global test

model term df1 df2 F.ratio p.value
age 1 136 0.067 0.8
modified_cg 1 136 4.485 0.04
bmi 1 136 5.469 0.02
enoxaparin_freq 1 136 4.915 0.03

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -0.405 (-0.939, 0.129) 0.1
age -0.001 (-0.006, 0.005) 0.8
modified_cg -0.003 (-0.006, -0.000) 0.04
bmi 0.009 (0.001, 0.017) 0.02
enoxaparin_freqTwice daily 0.221 (0.026, 0.416) 0.03

Model diagnostics

Results

Modified CrCl

Contrast Ratio of Geometric means (95% CI) P-value
modified_cg61 / modified_cg60 0.997 (0.994, 1.000) 0.04

BMI

Contrast Ratio of Geometric means (95% CI) P-value
bmi30 / bmi29 1.009 (1.001, 1.017) 0.02

Age

Contrast Ratio of Geometric means (95% CI) P-value
age67 / age66 0.999 (0.994, 1.005) 0.8

Dose frequency

Contrast Ratio of Geometric means (95% CI) P-value
Twice daily / Once daily 1.247 (1.024, 1.519) 0.03

Anti-Xa>1.0

Model specifications - Outcome: LMWH level >1.0 (yes/no)
- Covariates: age, modified CrCl, BMI, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ age + modified CrCl + BMI + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
age 2.981 1 0.08
modified_cg 9.309 1 0.002
bmi 5.865 1 0.02
enoxaparin_freq 4.568 1 0.03

Model summary

Var Coefficients (95% CI) P-value
(Intercept) 0.035 (-3.020, 3.091) 1.0
age -0.029 (-0.061, 0.004) 0.09
modified_cg -0.026 (-0.044, -0.008) 0.004
bmi 0.054 (0.009, 0.100) 0.02
enoxaparin_freqTwice daily 1.312 (0.059, 2.566) 0.04

Results

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 0.97 (0.96, 0.99) 0.004

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 1.06 (1.01, 1.10) 0.02

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 0.97 (0.94, 1.00) 0.09

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 3.72 (1.06, 13.01) 0.04

Anti-xa<0.5

Model specifications - Outcome: lmwh level <0.5 (yes/no)
- Covariates: age, modified crcl, bmi, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
age 0.176 1 0.7
modified_cg 1.482 1 0.2
bmi 1.396 1 0.2
enoxaparin_freq 3.631 1 0.06

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -1.393 (-6.752, 3.966) 0.6
age 0.011 (-0.042, 0.064) 0.7
modified_cg 0.015 (-0.010, 0.040) 0.2
bmi -0.052 (-0.146, 0.043) 0.3
enoxaparin_freqTwice daily -1.592 (-3.232, 0.049) 0.06

Results

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 1.02 (0.99, 1.04) 0.2

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 0.95 (0.86, 1.04) 0.3

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 1.01 (0.96, 1.07) 0.7

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 0.20 (0.04, 1.05) 0.06

Model 3: Individually dosed patients

Anti-Xa

Model specifications - Outcome: LMWH level
- Covariates: age, modified CrCl, BMI, dosing frequency
- Model: Multiple linear regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

Global test

model term df1 df2 F.ratio p.value
age 1 132 0.079 0.8
modified_cg 1 132 0.468 0.5
bmi 1 132 0.885 0.3
enoxaparin_freq 1 132 0.003 1.0

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -0.515 (-1.141, 0.111) 0.1
age 0.001 (-0.005, 0.007) 0.8
modified_cg 0.001 (-0.002, 0.004) 0.5
bmi 0.003 (-0.003, 0.008) 0.3
enoxaparin_freqTwice daily 0.005 (-0.166, 0.176) 1.0

Model diagnostics

Results

Modified CrCl

Contrast Ratio of Geometric means (95% CI) P-value
modified_cg61 / modified_cg60 1.001 (0.998, 1.004) 0.5

BMI

Contrast Ratio of Geometric means (95% CI) P-value
bmi30 / bmi29 1.003 (0.997, 1.008) 0.3

Age

Contrast Ratio of Geometric means (95% CI) P-value
age67 / age66 1.001 (0.994, 1.007) 0.8

Dose frequency

Contrast Ratio of Geometric means (95% CI) P-value
Twice daily / Once daily 1.005 (0.846, 1.194) 1.0

Anti-xa>1.0

Model specifications - Outcome: lmwh level >1.0 (yes/no)
- Covariates: age, modified crcl, bmi, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
age 0.898 1 0.3
modified_cg 0.279 1 0.6
bmi 0.974 1 0.3
enoxaparin_freq 0.407 1 0.5

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -3.990 (-8.124, 0.144) 0.06
age 0.020 (-0.022, 0.062) 0.3
modified_cg 0.005 (-0.013, 0.022) 0.6
bmi 0.017 (-0.016, 0.049) 0.3
enoxaparin_freqTwice daily 0.380 (-0.817, 1.578) 0.5

Results

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 1.00 (0.99, 1.02) 0.6

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 1.02 (0.98, 1.05) 0.3

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 1.02 (0.98, 1.06) 0.3

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 1.46 (0.44, 4.84) 0.5

Anti-xa<0.5

Model specifications - Outcome: lmwh level <0.5 (yes/no)
- Covariates: age, modified crcl, bmi, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
age 0.149 1 0.7
modified_cg 0.339 1 0.6
bmi 4.174 1 0.04
enoxaparin_freq 0.098 1 0.8

Model summary

Var Coefficients (95% CI) P-value
(Intercept) 0.900 (-3.482, 5.282) 0.7
age -0.009 (-0.052, 0.035) 0.7
modified_cg -0.006 (-0.025, 0.014) 0.6
bmi -0.047 (-0.097, 0.003) 0.07
enoxaparin_freqTwice daily -0.177 (-1.271, 0.918) 0.8

Results

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 0.99 (0.98, 1.01) 0.6

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 0.95 (0.91, 1.00) 0.06

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 0.99 (0.95, 1.04) 0.7

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 0.84 (0.28, 2.50) 0.8

Session info

Results generated on: 2023-11-03 21:18:56.546987

Click for more details

sessionInfo()
## R version 4.3.1 (2023-06-16)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.3 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0 
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
## 
## locale:
##  [1] LC_CTYPE=en_AU.UTF-8          LC_NUMERIC=C                 
##  [3] LC_TIME=en_AU.UTF-8           LC_COLLATE=en_AU.UTF-8       
##  [5] LC_MONETARY=en_AU.UTF-8       LC_MESSAGES=en_AU.UTF-8      
##  [7] LC_PAPER=en_AU.UTF-8          LC_NAME=en_AU.UTF-8          
##  [9] LC_ADDRESS=en_AU.UTF-8        LC_TELEPHONE=en_AU.UTF-8     
## [11] LC_MEASUREMENT=en_AU.UTF-8    LC_IDENTIFICATION=en_AU.UTF-8
## 
## time zone: Australia/Adelaide
## tzcode source: system (glibc)
## 
## attached base packages:
## [1] splines   grid      stats     graphics  grDevices utils     datasets  methods  
## [9] base     
## 
## other attached packages:
##  [1] progress_1.2.2    Hmisc_5.1-0       REDCapR_1.1.0     xlsx_0.6.5       
##  [5] ggpubr_0.6.0      DiagrammeR_1.0.10 car_3.1-2         carData_3.0-5    
##  [9] fontawesome_0.5.2 MASS_7.3-60       emmeans_1.8.8     plotly_4.10.2    
## [13] readxl_1.4.3      htmlwidgets_1.6.2 kableExtra_1.3.4  knitr_1.43       
## [17] ggplot2_3.4.3     devtools_2.4.3    usethis_2.2.2     pander_0.6.5     
## [21] magrittr_2.0.3    gridExtra_2.3     rmarkdown_2.24    nvimcom_0.9-145  
## 
## loaded via a namespace (and not attached):
##  [1] remotes_2.4.2.1    sandwich_3.0-2     rlang_1.1.1        multcomp_1.4-25   
##  [5] compiler_4.3.1     systemfonts_1.0.4  callr_3.7.3        vctrs_0.6.3       
##  [9] rvest_1.0.3        stringr_1.5.0      pkgconfig_2.0.3    crayon_1.5.2      
## [13] fastmap_1.1.1      backports_1.4.1    ellipsis_0.3.2     labeling_0.4.3    
## [17] utf8_1.2.3         sessioninfo_1.2.2  ps_1.7.5           purrr_1.0.2       
## [21] xfun_0.40          cachem_1.0.8       jsonlite_1.8.7     highr_0.10        
## [25] xlsxjars_0.6.1     broom_1.0.5        prettyunits_1.1.1  cluster_2.1.4     
## [29] R6_2.5.1           bslib_0.5.1        stringi_1.7.12     RColorBrewer_1.1-3
## [33] rpart_4.1.21       pkgload_1.3.2.1    jquerylib_0.1.4    cellranger_1.1.0  
## [37] estimability_1.4.1 Rcpp_1.0.11        zoo_1.8-12         base64enc_0.1-3   
## [41] nnet_7.3-19        Matrix_1.6-1.1     tidyselect_1.2.0   rstudioapi_0.15.0 
## [45] abind_1.4-5        yaml_2.3.7         codetools_0.2-19   processx_3.8.2    
## [49] pkgbuild_1.4.2     lattice_0.22-5     tibble_3.2.1       withr_2.5.0       
## [53] coda_0.19-4        evaluate_0.21      foreign_0.8-85     survival_3.5-7    
## [57] rJava_1.0-6        xml2_1.3.5         pillar_1.9.0       checkmate_2.2.0   
## [61] generics_0.1.3     hms_1.1.3          munsell_0.5.0      scales_1.2.1      
## [65] xtable_1.8-4       glue_1.6.2         lazyeval_0.2.2     tools_4.3.1       
## [69] data.table_1.14.8  webshot_0.5.5      ggsignif_0.6.4     fs_1.6.3          
## [73] visNetwork_2.1.2   mvtnorm_1.2-3      tidyr_1.3.0        colorspace_2.1-0  
## [77] htmlTable_2.4.1    Formula_1.2-5      cli_3.6.1          fansi_1.0.4       
## [81] viridisLite_0.4.2  svglite_2.1.1      dplyr_1.1.3        gtable_0.3.4      
## [85] rstatix_0.7.2      sass_0.4.7         digest_0.6.33      TH.data_1.1-2     
## [89] farver_2.1.1       memoise_2.0.1      htmltools_0.5.6    lifecycle_1.0.3   
## [93] httr_1.4.7